Progress report from the NIDA Addiction Research Center Baltimore, Maryland (1984).
D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D003192:Compulsive Behavior / Q000503:physiopathology* / Q000523:psychology; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004193:Discrimination Learning; D004723:Endorphins / Q000494:pharmacology*; D016314:Ethylketocyclazocine / Q000031:analogs & derivatives*; D005059:Euphoria / Q000187:drug effects; D005715:Gambling / Q000523:psychology; D005947:Glucose / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009538:Nicotine / Q000009:adverse effects*; D010465:Perception; D012119:Respiration / Q000187:drug effects; D019966:Substance-Related Disorders / Q000523:psychology; D013997:Time Factors
D004723:Endorphins; D009270:Naloxone; D016314:Ethylketocyclazocine; C012395:ketazocine; D009538:Nicotine; D009020:Morphine; D005947:Glucose; D003496:Cyclazocine